Galderma Raises 2026 Outlook Again as Dermatology Revenue Hits $4.77B
Swiss dermatology and aesthetics company Galderma Group AG (SIX: GALD) has raised its full-year 2026 sales guidance for the second consecutive quarter, reflecting strong demand across its skincare, injectables, and therapeutic dermatology divisions.
The company reported record nine-month net sales of $4.765 billion, up 25.1% year over year at constant currency and well ahead of analyst forecasts. Third-quarter sales reached $1.63 billion, up 26% at constant currency and approximately 5% above the average analyst estimate of $1.55 billion.
Growth across Galderma’s divisions included:
- Therapeutic dermatology: Up 64.4% to $1.347 billion for the nine-month period, driven largely by demand for Nemluvio.
- Injectable aesthetics: Up 13.2%.
- Dermatological skincare: Up 16.2%.
Galderma has raised its full-year 2026 net sales growth guidance to 22.5–23.5% at constant currency, up from its previous range of 19–21%. CEO Flemming Ørnskov cited “robust demand for our differentiated, premium portfolio” as the main driver.
For beauty and wellness consumers, the results underscore how premium skincare and aesthetic treatments are becoming mainstream priorities, even amid a challenging economic climate.
Source: Global Cosmetics News — Galderma Raises 2026 Sales Outlook for Second Consecutive Quarter